Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features

13 Feb 2020

Abstract excerpt

BACKGROUND: The programmed death receptor ligand 1 (PD-L1) immunohistochemistry (IHC) 22C3 pharmDx assay is a widely used selection method for pembrolizumab treatment in gastric cancer (GC) patients, especially in the U.S. The present study investigated the relationship between PD-L1 expression and the clinical features, molecular markers, and molecular subtypes of GC. METHODS: PD-L1 expression was assessed based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Ferroptosis and cancer prognosis
Share to Gastric Cancer Management and Outcomes

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32089413
DOI: 10.1016/j.prp.2020.152881

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 19 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular featuresPMID 32089413Read ↗

Impact of programmed death-ligand 1 (PD-L1) positivity on clinical and molecular features of patients with metastatic gastric cancer.Semantic proximity Read ↗

Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival.Semantic proximity Read ↗

Clinical Significance of Tumor and Immune Cell PD-L1 Expression in Gastric AdenocarcinomaSemantic proximity Read ↗

Clinicopathological features of Epstein-Barr virus infection, microsatellite instability, tumor mutation burden and PD-L1 status in Chinese patients with gastric cancerSemantic proximity Read ↗

Comprehensive assessment of PD-L1 and PD-L2 dysregulation in gastrointestinal cancers.Semantic proximity Read ↗

Clinicopathological Features of Epstein-Barr Virus Infection, Microsatellite Instability, Tumor Mutation Burden and PD-L1 Status in Chinese Patients with Gastric CancerSemantic proximity Read ↗

Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancerSemantic proximity Read ↗

Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric CancerSemantic proximity Read ↗

PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanismsSemantic proximity Read ↗

Polymorphism of the programmed death‐ligand 1 gene is associated with its protein expression and prognosis in gastric cancerSemantic proximity Read ↗

Immunohistochemical‐Based Molecular Typing of ACRG Combined With Immune‐Associated PD ‐ L1 Expression Can Predict the Prognosis of Gastric CancerSemantic proximity Read ↗

Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.